Human-centred design methods : developing scenarios for robot assisted play informed by user panels and field trials

Original article can be found at: http://www.sciencedirect.com/ Copyright ElsevierThis article describes the user-centred development of play scenarios for robot assisted play, as part of the multidisciplinary IROMEC1 project that develops a novel robotic toy for children with special needs. The project investigates how robotic toys can become social mediators, encouraging children with special needs to discover a range of play styles, from solitary to collaborative play (with peers, carers/teachers, parents, etc.). This article explains the developmental process of constructing relevant play scenarios for children with different special needs. Results are presented from consultation with panel of experts (therapists, teachers, parents) who advised on the play needs for the various target user groups and who helped investigate how robotic toys could be used as a play tool to assist in the children’s development. Examples from experimental investigations are provided which have informed the development of scenarios throughout the design process. We conclude by pointing out the potential benefit of this work to a variety of research projects and applications involving human–robot interactions.Peer reviewe

Deep Complex Convolutional Recurrent Network for Multi-Channel Speech Enhancement and Dereverberation

This paper proposes a neural network based system for multi-channel speech enhancement and dereverberation. Speech recorded indoors by a far field microphone, is invariably degraded by noise and reflections. Recent single channel enhancement systems have improved denoising performance, but do not reduce reverberation, which also reduces speech quality and intelligibility. To address this, we propose a deep complex convolution recurrent network (DCCRN) based multi-channel system, with integrated minimum power distortionless response (MPDR) beamformer and weighted prediction error (WPE) preprocessing. PESQ and STOI performance is evaluated on a test set of room impulse responses and noise samples recorded by the same setup. The proposed system shows a statistically significant improvement over competitive systems.acceptedVersio

Solidification of liquid metal drops during impact

Hot liquid metal drops impacting onto a cold substrate solidify during their subsequent spreading. Here we experimentally study the influence of solidification on the outcome of an impact event. Liquid tin drops are impacted onto sapphire substrates of varying temperature. The impact is visualised both from the side and from below, which provides a unique view on the solidification process. During spreading an intriguing pattern of radial ligaments rapidly solidifies from the centre of the drop. This pattern determines the late-time morphology of the splat. A quantitative analysis of the drop spreading and ligament formation is supported by scaling arguments. Finally, a phase diagram for drop bouncing, deposition and splashing as a function of substrate temperature and impact velocity is provided

Undersøkelse av støyplage ved norske flyplasser

-Det er gjennomført spørreundersøkelser om folks reaksjoner på støy ved fem norske flyplasser. Responsen er sammenlignet med tilsvarende undersøkelser internasjonalt. Resultatene viser at befolkningen i Norge gir uttrykk for å være mindre plaget enn gjennomsnittet internasjonalt. Resultatene indikerer at det ikke er noen grunn til å skjerpe grensene i Miljøverndepartementets retningslinje T-1442/2012 med hensyn på flystøy slik den reviderte utgaven av standarden ISO 1996 åpner for

Undersøkelse av støyplage ved norske flyplasser

-Det er gjennomført spørreundersøkelser om folks reaksjoner på støy ved fem norske flyplasser. Responsen er sammenlignet med tilsvarende undersøkelser internasjonalt. Resultatene viser at befolkningen i Norge gir uttrykk for å være mindre plaget enn gjennomsnittet internasjonalt. Resultatene indikerer at det ikke er noen grunn til å skjerpe grensene i Miljøverndepartementets retningslinje T-1442/2012 med hensyn på flystøy slik den reviderte utgaven av standarden ISO 1996 åpner for

Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

<p>Abstract</p> <p>Background</p> <p>High grade primary bone sarcomas are rare cancers that affect mostly children and young adults. Osteosarcoma and Ewing sarcoma are the most common histological subtypes in this age group, with current multimodality treatment strategies achieving 55-70% overall survival. As there remains an urgent need to develop new therapeutic interventions, we have reviewed published phase I/II trials that have been reported for osteosarcoma and Ewing sarcoma in the last twenty years.</p> <p>Results</p> <p>We conducted a literature search for clinical trials between 1990 and 2010, either for trials enrolling bone sarcoma patients as part of a general sarcoma indication or trials specifically in osteosarcoma and Ewing sarcoma. We identified 42 clinical trials that fulfilled our search criteria for general sarcoma that enrolled these patient groups, and eight and twenty specific trials for Ewing and osteosarcoma patients, respectively. For the phase I trials which enrolled different tumour types our results were incomplete, because the sarcoma patients were not mentioned in the PubMed abstract. A total of 3,736 sarcoma patients were included in these trials over this period, 1,114 for osteosarcoma and 1,263 for Ewing sarcoma. As a proportion of the worldwide disease burden over this period, these numbers reflect a very small percentage of the potential patient recruitment, approximately 0.6% for Ewing sarcoma and 0.2% for osteosarcoma. However, these data show an increase in recent activity overall and suggest there is still much room for improvement in the current trial development structures.</p> <p>Conclusion</p> <p>Lack of resources and commercial investment will inevitably limit opportunity to develop sufficiently rapid improvements in clinical outcomes. International collaboration exists in many well founded co-operative groups for phase III trials, but progress may be more effective if there were also more investment of molecular and translational research into disease focused phase I/II clinical trials. Examples of new models for early translational and early phase trial collaboration include the European based EuroBoNeT network, the Sarcoma Alliance for Research through Collaboration network (SARC) and the new European collaborative translational trial network, EuroSarc.</p

Initial solidification dynamics of spreading droplets

When a droplet is brought in contact with an undercooled surface, it wets the substrate and solidifies at the same time. The interplay between the phase transition effects and the contact-line motion, leading to its arrest, remains poorly understood. Here we reveal the early solidification patterns and dynamics of spreading hexadecane droplets. Total internal reflection (TIR) imaging is employed to temporally and spatially resolve the early solidification behaviour. With this, we determine the conditions leading to the contact-line arrest. We quantify the overall nucleation behaviour, \textit{i.e.} the nucleation rate and the crystal growth speed, and show its sensitivity to the applied undercooling of the substrate. By combining the Johnson-Mehl-Avrami-Kolmogorov nucleation theory and scaling relations for the spreading, we can calculate the temporal evolution of the solid area fraction, which is in good agreement with our observations. We also show that for strong enough undercooling it is the rapid growth of the crystals which determines the eventual arrest of the spreading contact line.Comment: 5 pages, 5 figure

On the lifetimes of evaporating droplets

The complete description of the lifetime of a droplet on a solid substrate evaporating in a 'stick–slide' mode is obtained. The unexpectedly subtle relationship between the lifetime of such a droplet and the lifetimes of initially identical droplets evaporating in the extreme modes (namely the constant contact radius and constant contact angle modes) is described and summarised in an appropriate master diagram. In particular, it is shown that the lifetime of a droplet is not, in general, constrained by the lifetimes of the extreme modes

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Background This phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and sunitinib failure. Patients and methods Patients were randomized 2:1 to nilotinib 400 mg b.i.d. or best supportive care (BSC; BSC without tyrosine kinase inhibitor, BSC+imatinib, or BSC+sunitinib). Primary efficacy end point was progression-free survival (PFS) based on blinded central radiology review (CRR). Patients progressing on BSC could cross over to nilotinib. Results Two hundred and forty-eight patients enrolled. Median PFS was similar between arms (nilotinib 109 days, BSC 111 days; P=0.56). Local investigator-based intent-to-treat (ITT) analysis showed a significantly longer median PFS with nilotinib (119 versus 70 days; P=0.0007). A trend in longer median overall survival (OS) was noted with nilotinib (332 versus 280 days; P=0.29). Post hoc subset analyses in patients with progression and only one prior regimen each of imatinib and sunitinib revealed a significant difference in median OS of >4 months in favor of nilotinib (405 versus 280 days; P=0.02). Nilotinib was well tolerated. Conclusion In the ITT analysis, no significant difference in PFS was observed between treatment arms based on CRR. In the post hoc subset analyses, nilotinib provided significantly longer median O